HRMY241115P50000
- 0.00
- 0.000.00%
Harmony Biosciences Newsroom
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences Is Maintained at Overweight by Cantor Fitzgerald
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Maintains Target Price $28
Cantor Fitzgerald Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $58
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $59
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Express News | Harmony Biosciences Holdings : Oppenheimer Raises Target Price to $59 From $56
Axonis Therapeutics Announces $115 Million Series A Financing
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript Summary
Harmony Biosciences Up Over 14%, on Track for Highest Close Since March 2023 -- Data Talk
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
Harmony Biosciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
Analyst Expectations For Harmony Biosciences's Future
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Harmony Biosciences Holdings Q3 Adjusted Earnings, Net Product Revenue Increase
Harmony Biosciences | 10-Q: Q3 2024 Earnings Report
Harmony Biosciences Reiterates 2024 Net Pdt Rev Guidance of $700M-$720M >HRMY
Harmony Biosciences: On Track to Submit SNDA for Pitolisant in Idiopathic Hypersomnia in 4Q >HRMY
Express News | Harmony Biosciences Q3 Pretax Profit USD 62.17 Million Vs. IBES Estimate USD 54 Million